Business context and reporting period
Intuitive Surgical, Inc. (Nasdaq: ISRG) filed this Form 10-K for the fiscal year ended December 31, 2019. Although the request identifies 2019 Q4, this is an annual filing; selected fourth-quarter results are included below. The company develops, manufactures, and services da Vinci robotic-assisted surgical systems and instruments, and began commercial sales of its Ion robotic-assisted lung-biopsy system in 2019. It reports one operating segment.
Financial performance
| Metric | FY 2019 | FY 2018 | Change |
|---|---|---|---|
| Revenue | $4.479 billion | $3.724 billion | +20% |
| Gross profit / margin | $3.110 billion / 69.4% | $2.604 billion / 69.9% | Margin down 0.5 percentage point |
| Operating income | $1.375 billion | $1.199 billion | +15% |
| Net income attributable to Intuitive | $1.379 billion | $1.128 billion | +22% |
| Diluted EPS | $11.54 | $9.49 | +22% |
| Cash from operating activities | $1.598 billion | $1.170 billion | +$429 million |
- Product revenue was $3.754 billion; service revenue was $724 million. Recurring revenue (instruments and accessories, service, and operating leases) reached $3.239 billion, or 72% of total revenue.
- Instruments and accessories revenue rose 23% to $2.408 billion; systems revenue rose 19% to $1.346 billion; service revenue rose 14% to $724 million.
- Cash, cash equivalents, and investments totaled $5.845 billion at year-end, versus $4.834 billion a year earlier. Current assets were $4.663 billion and current liabilities $1.030 billion. Total liabilities were $1.449 billion; the filing does not report borrowings or a conventional debt balance.
- Capital expenditures and purchases of property, equipment, and intellectual property were $426 million. Operating cash flow less these purchases was approximately $1.17 billion; this is a simple calculation, not a company-reported free-cash-flow measure.
- Fourth-quarter revenue was $1.278 billion versus $1.047 billion in Q4 2018; net income attributable to Intuitive was $358 million versus $293 million. Diluted EPS was $2.99 versus $2.45.
Material changes versus the prior comparable period
- Worldwide da Vinci procedures increased 18% to approximately 1.229 million; the installed base grew 12% to 5,582 systems. System shipments rose 21% to 1,119.
- U.S. revenue was 70% of the total, down from 71%; OUS revenue grew to 30% from 29%. OUS procedure growth was approximately 21%, compared with 17% in the U.S.
- Gross margin eased to 69.4% from 69.9%, partly reflecting higher intangible-asset amortization. Operating expenses rose 24% to $1.736 billion, including R&D up 33% to $557 million as the company expanded product-development investment.
- Inventory increased to $596 million from $409 million, contributing to operating cash use from working-capital changes. Property, plant, and equipment, net, rose to $1.273 billion from $812 million.
- Income tax expense fell to $120 million from $155 million; the effective tax rate was 8.0% versus 12.1%. The 2019 rate included a $51.3 million Swiss deferred-tax benefit and substantial share-based compensation tax benefits.
Outlook, management commentary, risks, and unusual items
- Management said it expects substantial and increasing R&D investment. It expects capital investments to exceed $400 million in each of the next two years, funded from operating cash flow. The filing provides no specific revenue or earnings guidance.
- Ion and da Vinci SP were early-stage launches introduced in a measured fashion to develop training pathways, supply capacity, and clinical data. At year-end, 10 Ion systems were in commercial use and 44 da Vinci SP systems were installed. Ion’s 2019 revenue and gross-margin impact was described as not significant.
- The company acquired Schölly endoscope assets and operations for $101.4 million; $37.3 million of purchase consideration remained deferred at year-end, with payments tied to integration steps expected to conclude around the end of 2020. The Fosun joint venture also acquired Chindex China-distribution assets; the transaction included $64.7 million of contingent consideration. The joint venture did not expect revenue from catheter-based devices in 2020.
- Unusual items included $338 million of share-based compensation expense, $67.2 million of intangible-asset charges, and a $269.5 million share repurchase. The company recorded $0.5 million in 2019 litigation charges, compared with $45.2 million in 2018, including the prior-year $42.5 million securities-class-action settlement.
- Material risks include competition from established and emerging robotic-surgery providers; reliance on procedure adoption, hospital capital budgets, reimbursement, and regulatory clearances; supply-chain and sole-source supplier exposure; foreign-exchange, trade, and tariff risks; and product quality, liability, and cybersecurity risks.
- Ethicon patent disputes involving staplers were pending, including a U.S. International Trade Commission investigation with a hearing scheduled for April 2020; an adverse outcome could restrict imports or require product changes. The company could not reasonably estimate losses from the patent matters. It also faced individual product-liability cases and a Restore Robotics antitrust case; possible losses beyond recorded amounts could not be estimated. Intuitive self-insures product-liability risk.
- The filing notes epidemic and pandemic disruption as a risk, including the then-recent novel coronavirus, but does not quantify any resulting financial impact. The medical-device excise tax was repealed in December 2019.
Most important facts for investors to verify
- Whether procedure growth, recurring instrument revenue, and system utilization continue to support growth, particularly in general surgery, China, and other OUS markets.
- How leasing and usage-based placements affect revenue timing, cash conversion, customer credit exposure, and future system buyouts.
- Whether gross-margin pressure, rising R&D and capital spending, and inventory growth remain manageable as new products scale.
- Developments in the Ethicon patent/ITC proceedings, product-liability claims, and Restore Robotics litigation, including any change in loss estimates or operating restrictions.
- Integration progress and remaining obligations for the Schölly and Chindex transactions, including contingent and deferred payments.
- The sustainability of the unusually low 2019 effective tax rate and the outcome of tax uncertainties, including the share-based-compensation tax position.